News

Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna
Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Septerna (SEPN) for obesity pills — the ...
Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills — Update
Under the terms of the agreement, Septerna is eligible to receive around $2.2 billion from Novo Nordisk, including more than $200 million in upfront and near-term milestone payments.